Has science found a way to get villainous clumps of protein to cure instead of kill? Possibly, say European researchers whose early-stage findings might spur a new class of cancer therapeutics.

The team created an artificial protein containing amyloids — sequences that, under the right conditions, cause proteins to clump together. Those clumps are seen in the brains of people with neurodegenerative diseases like Alzheimer’s and Parkinson’s. The researchers wanted to know: Could they create synthetic versions of those tangles and use them to halt the flow of blood to a tumor — and thus stop the cancer in its tracks?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy